Selective Inhibition of Phosphodiesterase 7 (PDE7) by BRL50481 in Healthy and Ovalbumin-Sensitized Guinea Pigs

Ichimura M. Kase H. A new cyclic nucleotide phosphodiesterase isoenzyme expressed in the T-lyphocyte cell lines. Biochem Biophys Res Commun 1993; 193: 985-90.10.1006/bbrc.1993.1722Search in Google Scholar

Nakata A, Ogawa K, Sasaki T, Koyama N, Wada K, Kotera J, Kokkawa H, Omori K, Kaminuma O. Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol 2002; 128: 460-6.10.1046/j.1365-2249.2002.01856.xSearch in Google Scholar

Jones NA, Leport M, Holand T, Vos T, MOrgan M, Fink M, Pruniaux MP, Berthelier C, O'Connor BJ, Bertrand C, Page CP. Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD. Pulm Pharmacol Therap 2007; 20: 60-8.10.1016/j.pupt.2005.11.010Search in Google Scholar

Kadoshima-Yamaoka K, Murakawa M, Goto M, Tanaka Y, Inoue H, Murafuji H, Nagahira A, Hayashi Y, Kagahira K, Miura K, Nakatsuka T, Chamoto K, Fukuda Y, Nishimura T. ASB16165, a novel inhibitor for phos-phodiesterase 7A (PDE7A), supresses IL-12-induced IFN- production by mouse activated T lymphocytes. Immunol Letters 2009; 122: 193-7.10.1016/j.imlet.2009.01.004Search in Google Scholar

Mokry J, Nosalova G, Mokra D. Influence of xanthine derivatives on cough and airway reactivity in guinea pigs. J Physiol Pharmacol 2009; 60 (Suppl 5): 87-91.Search in Google Scholar

Mokra D, Mokry J. Meconium aspiration syndrome. From pathomechanisms to treatment. 1st ed. Nova Science Publishers: New York, 2010, 130 p.Search in Google Scholar

Nosalova G, Mokry J. The mechanism of action of xanthine derivatives and suppression of cough. Acta Med Mart 2001; 1: 14-8.Search in Google Scholar

Usmani OS, Belvisi MG, Patel HJ, et al. Theobromine inhibits sensory nerve activation and cough. FASEB J 2004: 2-16.10.1096/fj.04-1990fjeSearch in Google Scholar

Antoniu SA. Roflumilast for the treatment of chronic obstructive pulmonary disease. Curr Opin Investig Drugs 2006; 7: 412-7.Search in Google Scholar

Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005; 365: 167-75.10.1016/S0140-6736(05)17708-3Search in Google Scholar

Spina D, Landells LJ, Page CP. The role of theophylline and phosphodiesterase4 isoenzyme inhibitors as anti-inflammatory drugs. Clin Exp Allergy 1998; 28 (Suppl 3): 24-34.Search in Google Scholar

Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011; 32(8): 495-505.10.1016/j.tips.2011.04.00321683458Search in Google Scholar

Chung KF. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 2006; 533: 110-7.10.1016/j.ejphar.2005.12.05916458289Search in Google Scholar

Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008; 155: 308-15.10.1038/bjp.2008.307256789218660825Search in Google Scholar

Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol Rev 2006; 58: 488-520.10.1124/pr.58.3.516968949Search in Google Scholar

Karish SB, Gagnon JM. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor. Ann Pharmacother 2006; 40: 1096-104.10.1345/aph.1E651Search in Google Scholar

Fabbri LM, Beghe B, Yasothan U, Kirkpatrick P. Roflumilast. Nature Reviews Drug Discovery 2010; 9: 761-762.10.1038/nrd3276Search in Google Scholar

Giembycz MA, Field SK. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther 2010; 4: 147-158.Search in Google Scholar

Mokry J, Mokra D, Nosalova G, Beharkova M, Feherova Z. Influence of selective inhibitors of phosphodiesterase 3 and 4 on cough and airway reactivity. J Physiol Pharmacol 2008; 59 (suppl. 6): 473-82.Search in Google Scholar

Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS, Giembycz MA. Discovery of BRL 50481 [3-(N, N-dimethylsulfonamido)-4-methyl-nitrobenzene], a Selective Inhibitor of Phosphodiesterase 7: In Vitro Studies in Human Monocytes, Lung Macrophages, and CD8+ T-Lymphocytes. Molecular Pharmacology 2004; 66(6): 1679-1689.10.1124/mol.104.002246Search in Google Scholar

Morales-Garcia JA, Redondo M, Alonso-Gil S, Gil C, Perez C, Martinez A, Santos A, Perez-Castillo A. Phosphodiesterase 7 Inhibition Preserves Dopaminergic Neurons in Cellular and Rodent Models of Parkinson Disease. PLoS ONE 2011; 6(2): e17240.10.1371/journal.pone.0017240Search in Google Scholar

Franova S, Nosalova G, Pechanova O, Sutovska M. Red wine polyphenolic compounds inhibit tracheal smooth muscle contraction during allergen-induced hyperreactivity of the airways. J Pharm Pharmacol 2007; 59: 727-32.10.1211/jpp.59.5.0014Search in Google Scholar

Sutovska M, Franova S, Sutovsky J. The influence of animal species on the relationship between ATP-sensitive potassium ion channels and defense reflexes of the airways. Bratisl Med J 2009; 110 (5), 269-275.Search in Google Scholar

Strapkova A, Nosalova G, Banovcin P, Giacova D. Changes in airway smooth muscle reactivity after exposure to toluene. Stud Pneumol Phthiseol 1995; 55: 263-71.Search in Google Scholar

Javorka K, Calkovska A, Mokra D, Tonhajzerova I. Medical Physiology. Laboratory Manual. Comenius University, Bratislava, 2006, p. 143.Search in Google Scholar

Beeh KM, Beier J, Lerch C, Schulz AK, Buhl R. Effects of Piclamilast, a Selective Phosphodiesterase-4 Inhibitor, on Oxidative Burst of Sputum Cells From Mild Asthmatics and Stable COPD Patients. Lung 2004; 182: 369-77.10.1007/s00408-004-2518-zSearch in Google Scholar

Giembycz MA. Phosphodiesterase-4: Selective and Dual-Specificity Inhibitors for the Therapy of Chronic Obstructive Pulmonary Disease. Proc American Thor Soc 2005b; 2: 326-33.10.1513/pats.200504-041SRSearch in Google Scholar

Rabe KF, Bateman ED, O'Donnel D, Witte S, Bredenbroker D, Bethke TD. Roflumilast: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366: 563-71.10.1016/S0140-6736(05)67100-0Search in Google Scholar

Ghosh R, Sawant O, Ganpathy P, Pitre S, Kadam VJ. Phosphodiesterase inhibitors: their role and implications. Int J PharmTech Res 2009; 1(4): 1148-60.Search in Google Scholar

Paterniti I, Mazzon E, Gil C, Impellizzeri D, Palomo V, Redondo M, Perez DI, Esposito E, Martinez A, Cuzzocrea S. PDE7 inhibitors: new potential drugs for the therapy of spinal cord injury. PLoS ONE 2011; 6(1): e15937.10.1371/journal.pone.0015937303152421297958Search in Google Scholar

Guo J, Watson A, Kempson J, Carlsen M, Barbosa J, Stebbins K, Lee D, Dodd J, Nadler SG, McKinnon M, Barrish J, Pitts WJ. Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation. Bioorganic Medicinal Chmistry Letters 2009; 19: 1935-8.10.1016/j.bmcl.2009.02.06019272774Search in Google Scholar

Pitts WJ, Vaccaro W, Huynh T, Leftheris K, Roberge JY, Barbosa J, Guo J, Brown B, Watson A, Donaldson K, Starling GC, Kiener PA, Poss MA, Dodd JH, Barrish JC. Identification of purine inhibitors of phosphodiesterase 7 (PDE7). Bioorganic Medicinal Chemistry Letters 2004; 14: 2955-8.10.1016/j.bmcl.2004.03.02115125967Search in Google Scholar

Fortin M, D'Anjou H, Higgins ME, Gougeon J, Aube P, Moktefi K, Mouissi S, Seguin S, Seguin R, Renzi PM, Paquet L, Ferrari N. A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice. Respiratory Res 2009; 10:39.10.1186/1465-9921-10-39269643719457265Search in Google Scholar

Giembycz MA. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol 2005a; 5: 238-44.10.1016/j.coph.2005.04.00115907909Search in Google Scholar